Replies to post #6221 on Grapefruit USA Inc (GPFT)

[Chemic76spirit]

has nothing to do with FDA, only RSNA and postponed shareholder meeting; but I'm sure you can ask questions that Dean doesn't have the answers for yet.

[Baruch Lebovits]

DJ IN THE MONEY: More Patience Asked Of Imaging3 Shareholders

By Carol S. Remond

A DOW JONES NEWSWIRES COLUMN

Patience is king when it comes to Imaging3 Inc. (IMGG).
First, there was the long-delayed, and still missing, clearance for commercialization by the U.S. Food and Drug Administration of Imaging3's Dominion medical scanner. Now, there is a postponing of Imaging3's shareholder meeting,
originally scheduled for Dec. 10, until next year.
Imaging3 Chief Executive Dean Janes wasn't immediately available to comment. But the wording of the company's press release Monday suggests that the U.S. Securities and Exchange Commission has yet to approve Imaging3's proxy statement.
Imaging3 said in the release that the shareholder meeting "requires SEC approval, which has not yet been received from the SEC at this time." While the SEC doesn't "approve" shareholder meetings, it does
review proxy statements and, on occasion, comments on them.
It does sound like the SEC might have had a number of comments with its comes to Imaging3's preliminary proxy statement filed on Oct. 9.
Meanwhile, shareholders are still awaiting FDA clearance of Imaging3's Dominion scanner.
CEO Janes first told investors on Oct. 29 his company might be cleared to market its mobile scanner by the end of November. Alas, November ended without FDA clearance announcement.
Janes' optimism led to huge spikes in Imaging3 stock price and trading volume. The stock, which topped at $1.95 a share on Nov. 13, closed Monday down 3.7%, at $1.21 a share. Imaging3 stock had been trading at around 5 cents until early September before online promotions started inviting investors to take a closer look at the
company.
Anxious shareholders might get some answers Wednesday when Janes, according to another company press release Monday, will update shareholders about a recent trade show he attended and "other recent developments important to the company and its Shareholders."
Stay tuned.

(Carol S. Remond, a special writer on the In The Money team, is an award-winning columnist who won a Gerald Loeb Award in 2005 for best news service content with "Exposing Small-Cap fraud," a series of articles that described how three small companies unscrupulously pumped up their stocks. She can be reached at 303-997-5783 or by
e-mail: [e-mail])